Celcuity’s Revtorpyk (gedatolisib) cleared FDA approval for HR-positive/HER2-negative locally advanced or metastatic breast cancer in patients without a PIK3CA mutation after progression on endocrine therapy. The regulator positioned Revtorpyk as the first PAM pathway inhibitor in the indication, giving Celcuity its first commercial product and a new lever for PI3K-pathway treatment selection. The company disclosed a launch delay, which weighed on investor sentiment despite the approval. Analysts and clinicians were focused on the exact patient subset in the prescribing information and how quickly commercial uptake can translate into revenue. Separately, the broader oncology pipeline continued to show regulatory momentum alongside risk management around commercialization timelines—an issue that is now shaping near-term biotech valuation more than efficacy alone.